A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

Inclusion criteria: * Patients with a documented diagnosis of HS (e.g., International Classification of Diseases, 10th Revision \[ICD-10\] code L73.2); * Age ≥18 years at index date; * Moderate-to-severe HS as per label; * Initiation of secukinumab treatment on or after the first HS diagnosis date; * And at least one follow-up assessment at 6 or 12 months after index date. Exclusion criteria: * Patients who had major HS-related surgery (Skin-tissue-sparing Excision with Electrosurgical Peeling \[STEEP\] or wide excision) in the 12 months prior to index date; * Patients participating in interventional clinical trials at index date. Other protocol-defined inclusion/exclusion criteria may apply.